ClinicalTrials.gg
CompletedNCT05525637Updated Jun 30, 2026

Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

A Phase 3 interventional study of YZJ-1139 20mg and YZJ-1139 40mg in Insomnia Disorder, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 83 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2021, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,037
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
2nd of 162
1,037 · median 88
Started
2021
with 16 others
Phase 3
7 of 198
1 open now
Registered
61st of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 2nd largest by enrollment of the 162 interventional ones that give a count, is one of 17 that started in 2021, is one of 7 in phase 3, and was the 61st registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Subjects who meet all of the following criteria may be enrolled in the study:

  1. Aged ≥ 18 to \< 65 years.
  2. Meet the clinical diagnostic criteria for insomnia disorder as defined in International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria.
  3. sTSO ≥ 30 min for at least 3 nights per week and/or sWASO ≥ 60 min for at least 3 nights per week within 28 days (4 weeks) prior to screening.
  4. During the run-in period or on Day 1 of the treatment period, sTSO ≥ 30 min for at least 3 nights in the last 7 sleep diaries and/or sWASO ≥ 60 min for at least 3 nights out of 7 nights as confirmed by the sleep diary prior to Polysomnography (PSG) monitoring.
  5. PSG results for 2 consecutive nights during the run-in period should meet the following conditions:

    • The mean LPS of 2 nights is ≥ 30 min, with the LPS ≥ 20 min for any night;
    • And/or the mean WASO of 2 nights is ≥ 60 min, with neither night \< 45 min;
    • The mean SE of 2 nights is ≤ 85%, with the SE ≤ 87.5% for both nights.
  6. ISI score ≥ 15 at screening and on Day 1 of the treatment period.
  7. Agree to follow the habitual bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m. every day, and stay in bed for 6.5 to 9 hours per night during the study.
  8. Have a bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m., and stay in bed for 6.5 to 9 hours for at least 5 days in the last 7 sleep diaries as confirmed by the sleep diary prior to PSG monitoring during the run-in period or on Day 1 of the treatment period.
  9. Female subjects are confirmed to be non-pregnant at screening; both men of and women of should agree to use medically acceptable and effective throughout the study and within 3 months after the end of the study.
  10. Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Form (ICF), have good compliance during participation in the study, and are willing to attend the visits.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria should be excluded from this study:

    1. Depression: Hamilton Depression Scale (HAMD) score ≥ 18; anxiety: Hamilton Anxiety Scale (HAMA) score ≥ 14.
    2. Suicidal ideation with or without plan at screening or within 6 months prior to screening (score ≥ 3 on item 3 [suicide] of HAMD, or select "Yes" on item 3, 4 or 5 of suicidal ideation subscale of Columbia-Suicide Severity Rating Scale (C-SSRS)), or have any suicidal behavior in the past 10 years (as assessed by the suicidal ideation subscale of C-SSRS).
    3. Apnea-hypopnea index (AHI) and/or periodic limb movement index (PLMI) > 10 times/hour detected by PSG monitoring during the run-in period.
    4. Repeat (ECG) at screening shows interval prolongation (QTcF > 450 ms) (the ECG should be repeated 2 more times only if the initial ECG shows QTcF interval > 450 ms).
    5. Have serious endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, diseases, impaired respiratory function or other related diseases, or have other medical history that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
    6. Have insomnia disorder due to other causes such as chronic pain, headache, eczema, neurodermatitis, allergic rhinitis, and serious dermatitis (difficulty sleeping due to physical reasons, difficulty falling asleep due to medical reasons).
    7. Previous history of nervous system disorders such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
    8. Previous history of sleep-related respiratory disorders including obstructive sleep apnea (with or without continuous positive airway pressure (CPAP) therapy), periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disturbances, narcolepsy or other sleep disorders: subjects with restless legs syndrome which is diagnosed by relevant diagnostic and treatment guidelines should be excluded.
    9. Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
    10. Plan to undergo surgery during the study.
    11. Have received any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, cytochrome P450 3A () inducers, CYP3A inhibitors, traditional Chinese medicines and traditional Chinese medicinal products with sleep-improving effects, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the product, whichever is longer.
    12. History of drug taking or addiction, which is known through questioning.
    13. Have any lifestyle that interferes with the study process or may interfere with sleep: for example, there will be travels across 3 or more time zones (mainland China is considered as 1 time zone) within the next 2 weeks or during the study period, or there will be shift work (night and daytime shift).
    14. (AST) and alanine aminotransferase (ALT) > 2 × the (ULN), or Creatinine (Cr) > 1.5 × ULN.
    15. Hyperthyroidism.
    16. History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor) within the past 2 years.
    17. History of drug abuse within the past 2 years, or positive urine drug screening for any indicator.
    18. Regular daily consumption of excessive tea and coffee drinks (defined as consumption of > 4 cups of caffeinated beverages or > 400 mg of caffeine per day), or daily habituation to drinking caffeinated beverages beyond 18:00.
    19. Have nocturia increased caused by urinary tract infection, urinary tract injury or prostatic disorder.
    20. Have positive infectious disease screening for surface antigen (HBsAg), antibody (HCVAb) and (HIV) antibody at screening.
    21. Unable to avoid vaccination within 1 month prior to screening or during the first treatment phase.
    22. Have participated in clinical studies of other drugs within the past 1 month or 5 half-lives (whichever is longer), or plan to participate in other studies simultaneously during participation in this study.
    23. Pregnant or lactating women.
    24. History of allergy to the investigational product or its components.
    25. Have prior participation in clinical studies of YZJ-1139 Tablets.
    26. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,037 participants (actual)

Study arms

  • Experimental
    YZJ-1139 20mg

    Drug: YZJ-1139 20mg

  • Experimental
    YZJ-1139 40mg

    Drug: YZJ-1139 40mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • YZJ-1139 20mg tablets, once daily in the evening

  • YZJ-1139 40mg tablets, once daily in the evening

  • DrugPlacebo

    Match placebo tablets, once daily in the evening

06

What researchers measure

Primary outcomes

  1. Change from baseline in the subjective sleep efficiency (sSE) after 14 days of treatment

    Subjective Sleep efficiency variation assessed by the sleep diary questionnaire at 14 days of treatment from baseline. A positive change from baseline indicates an increase in the subjective Sleep efficiency. A negative change from baseline indicates a decrease in subjective Sleep efficiency

    Time frame: from baseline to week 2

  2. Change from baseline in the sleep efficiency (SE) after 14 days of treatment

    Sleep efficiency variation assessed by polysomnography at 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

    Time frame: from baseline to day 14

Secondary outcomes

  1. Change from baseline in the subjective sleep efficiency (sSE) after 7 days of treatment

    sSE is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, week 1

  2. Changes from baseline in the Subjective time to sleep onset (sTSO) after 14 days of treatment for subjects entering the second treatment phase

    sTSO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, week 1, week 2

  3. Changes from baseline in the Subjective wake after sleep onset (sWASO) after 14 days of treatment for subjects entering the second treatment phase

    sWASO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, week 1, week 2

  4. Changes from baseline in the Subjective total sleep time (sTST) after 14 days of treatment for subjects entering the second treatment phase

    sTST are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, week 1, week 2

  5. Changes from baseline in the Subjective number of awakenings (sNAW) after 14 days of treatment for subjects entering the second treatment phase

    sNAW are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, week 1, week 2

  6. Changes from baseline in the SE after 2 days of treatment

    SE assessed by polysomnography at 2 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

    Time frame: Baseline, Day1/Day2

  7. Latency to persistent sleep (LPS) after 2 and 14 days of treatment

    LPS assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

    Time frame: Baseline, Day1/Day2, Day13/Day14

  8. Wake after sleep onset (WASO) after 2 and 14 days of treatment

    WASO assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

    Time frame: Baseline, Day1/Day2, Day13/Day14

  9. Total sleep time (TST) after 2 and 14 days of treatment

    TST assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

    Time frame: Baseline, Day1/Day2, Day13/Day14

  10. Sleep structure (wakefulness, N1, N2, N3, rapid eye movement sleep [REM], non-rapid eye movement sleep [NREM], REM latency, number of awakenings [NAW], arousal index for REM and NREM) after 2 and 14 days of treatment

    Sleep structure assessed by polysomnography at 2 and 14 days of treatment from baseline.

    Time frame: Baseline, Day1/Day2, Day13/Day14

  11. Change from baseline in the mean subjective sleep quality score after 7 and 14 days of treatment for subjects

    Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.

    Time frame: Baseline, Week 1, Week 2

  12. Percentage of Participants on each scale of Global Impression of Insomnia (PGI-I) each Item at 14 days of treatment

    The PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak)

    Time frame: Day 14

  13. Changes from baseline in the sSE after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    sSE are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  14. Changes from baseline in the sTSO after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    sTSO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  15. Changes from baseline in the sWASO after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    sWASO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  16. Changes from baseline in the sTST after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    sTST are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  17. Changes from baseline in the sNAW after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    sNAW are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  18. Change from baseline in the mean subjective sleep quality score after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  19. Change from baseline in the Insomnia Severity Index (ISI) score after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    ISI is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Higher score indicated severe insomnia problem.

    Time frame: Baseline, Day 30, Day 90, and Day 180

  20. Percentage of Participants who enter the second treatment phase on each scale of Patient Global Impressions - ImprovementGlobal Impression of Insomnia (PGI-I) each Item at 30, 90 and 180 days of treatment

    The PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak).

    Time frame: Day 30, Day 90, and Day 180

07

Study locations

83 sites
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, China
  • Beijing Hui Long Guan Hospital, Capital Medical University
    Beijing, China
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, China
  • China-Japan Friendship Hospital
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • Xuanwu Hospital Capital Medical University
    Beijing, China
  • The First affiliated hospital of bengbu medical college
    Bengbu, China
  • Binzhou Medical University Hospital
    Binzhou, China
  • The First Bethune Hospital Of Jilin University
    Changchun, China
  • The First Hospital of ChangSha
    Changsha, China
  • The Second XiangYa Hospital Of Central University
    Changsha, China
  • The Secong People's Hospital Of HuNan Province
    Changsha, China
  • Xiangya Hospital Central South University
    Changsha, China
  • The Fourth People's Hospital Of ChengDu
    Chengdu, China
  • Army Medical Center of PLA
    Chongqing, China
  • ChongQing Eleventh People's Hospital
    Chongqing, China
  • ChongQing Mental Health Center
    Chongqing, China
  • ChongQing Traditional Chinese Medical Hospital
    Chongqing, China
  • ChongQing University Three Gorges Hospital
    Chongqing, China
  • People's Hospital Of DeYang City
    Deyang, China
  • The First Affiliated Hospital Of FuJan Medical University
    Fuzhou, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Nanfang Hospital Southern Medical University
    Guangzhou, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, China
  • The Affiliated Hospital Of GuiZhou Medical University
    Guiyang, China
  • HanDan Central Hospital
    Handan, China
  • Affiliated HangZhou First People's Hospital
    Hangzhou, China
  • Sir Run Run Shaw hospital
    Hangzhou, China
  • The 2nd Affiliated Hospital Of Harbin Medical University
    Ha’erbin, China
  • Chaohu hospital of anhui medical university
    Hefei, China
  • The Second Hospital Of AnHui Medical University
    Hefei, China
  • The Secong People's Hospital Of HeFei
    Hefei, China
  • Affiliated NanHua Hospital,University Of South China
    Hengyang, China
  • JiangMen Central Hospital
    Jiangmen, China
  • ShanDong Provincial QianFoShan Hospital
    Jinan, China
  • Jingjiang People's Hospital
    Jingjiang, China
  • Shandong Daizhuang Hospital
    Jining, China
  • Jiujiang University Affiliated Hospital
    Jiujiang, China
  • First People's Hospital of Yunnan Province
    Kunming, China
  • LiaoCheng People's Hospital
    Liaocheng, China
  • HeNan University Of Science &Technology
    Luoyang, China
  • The Affiliated Hospital Of Southwest Medical University
    Luzhou, China
  • JiangXi Provincial People's Hospital
    Nanchang, China
  • The First Affiliated Hospital Of NanChang University
    Nanchang, China
  • The Second Affiliated Hospital Of NanChang University
    Nanchang, China
  • Zhongda Hospital Southeast Unveristy
    Nanjing, China
  • NanTong First People's Hospital
    Nantong, China
  • NingBo KangNing Hospital
    Ningbo, China
  • NingBo Medical Center LiHuiLi Hospital
    Ningbo, China
  • QingDao Center Medical Group
    Qingdao, China
  • QingDao Municipal Hospital
    Qingdao, China
  • The affilated hospital of qingdao university
    Qingdao, China
  • The 2nd Affiliated Hospital Of FuJan Medical University
    Quanzhou, China
  • Affiliated ZhongShan Hospital,University Of FuDan
    Shanghai, China
  • HuaShan Hospital Fudan University
    Shanghai, China
  • ShengJing Hospital Of China Medical University
    Shenyang, China
  • ShenZhen People's Hospital
    Shenzhen, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, China
  • Jilin Neuropsychiatric Hospital
    Siping, China
  • SuZhou GuangJi Hospital
    Suzhou, China
  • The First People's Hospital Of KunShan
    Suzhou, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, China
  • First Hospital Of ShanXi Medical University
    Taiyuan, China
  • Peking University BinHai Hospital
    Tianjin, China
  • Tianjin Huanhu Hospital
    Tianjin, China
  • Tianjin Mental Health Center
    Tianjin, China
  • The Center Hospital of WuHan
    Wuhan, China
  • Wuhan Mental Health Centre
    Wuhan, China
  • Affiliated Hospital Of Jiangnan University
    Wuxi, China
  • WuXi People's Hospital
    Wuxi, China
  • Air Force Medical University
    Xi'an, China
  • XianYang Hospital OF Yan'an University
    Xianyang, China
  • HeNan Mental Hospital
    Xinxiang, China
  • The Affiliated Hospital Of XuZhou Medical University
    Xuzhou, China
  • XuZhou Central Hospital
    Xuzhou, China
  • The First Affiliated Hospital Of ZhenZhou University
    Zhengzhou, China
  • ZhenZhou Central Hospital
    Zhengzhou, China
  • ZhenJiang Mental Health Center
    Zhenjiang, China
  • ZhuMaDian Second People's Hospital
    Zhumadian, China
  • ZiGong First People's Hospital
    Zigong, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jul 2023, 18 months.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 18 months is close to that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Sep 1, 2022
StartActual
Dec 17, 2021
Primary completionActual
Jul 7, 2023
CompletionActual
Sep 27, 2023
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05525637
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 1, 2022
Start date
Dec 17, 2021
Primary completion
Jul 7, 2023
Completion
Sep 27, 2023
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion